LWM
CRSP icon

Liberty Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Liberty Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-96
Closed -$11K – 353
2021
Q3 		$11K Buy
96
+4
+4% +$502 ﹤0.01% 802
2021
Q2 		$15K Hold
92
– – 0.01% 562
2021
Q1 		$15K Hold
92
– – 0.01% 511
2020
Q4 		$15K Hold
92
– – 0.01% 509
2020
Q3 		$8K Hold
92
– – ﹤0.01% 551
2020
Q2 		$7K Hold
92
– – ﹤0.01% 541
2020
Q1 		$4K Hold
92
– – ﹤0.01% 607
2019
Q4 		$5K Hold
92
– – ﹤0.01% 658
2019
Q3 		$4K Buy
+92
New +$4.4K ﹤0.01% 662

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Liberty Wealth Management's CRSP Position: Q4 2021 in Review

Liberty Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 96 shares — an estimated $11K sold.

Liberty Wealth Management first reported a position in CRSP in Q3 2019 and held it in 9 quarters. The position peaked at $15K in Q2 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • Liberty Wealth Management reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Liberty Wealth Management sold 96 CRISPR Therapeutics shares in Q4 2021, an estimated $11K.
  • Liberty Wealth Management first reported a position in CRISPR Therapeutics in Q3 2019 and held it in 9 quarters.
  • Liberty Wealth Management's CRISPR Therapeutics position peaked at $15K in Q2 2021.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Liberty Wealth Management's 13F filing for Q4 2021, filed 15 Feb 2022.